Adults with recurrent migraine attacks may be prescribed Sibelium to reduce how often headaches occur. Sibelium contains flunarizine, a calcium-channel blocker that helps limit excessive calcium…
Adults with recurrent migraine attacks may be prescribed Sibelium to reduce how often headaches occur. Sibelium contains flunarizine, a calcium-channel blocker that helps limit excessive calcium movement in nerve and vascular cells. It is used for prevention, not for immediate relief during an active migraine.
Sibelium contains flunarizine, a selective calcium-channel blocker with effects on neuronal and vascular excitability. Flunarizine reduces excessive calcium entry into cells, which can help stabilise nerve pathways involved in migraine and reduce abnormal vascular reactivity.
Sibelium is primarily associated with migraine prophylaxis. Preventive treatment is considered when migraine attacks are frequent, prolonged, disabling, or poorly controlled with acute treatment alone. The aim is to lower attack frequency and intensity over time.
Flunarizine may also be used in selected patients with vertigo or vestibular symptoms when a clinician considers the medicine appropriate. Its use for circulation problems depends on the diagnosis and the prescribing clinician’s assessment; it should not be treated as a general remedy for every cold hand, leg symptom, or dizziness episode.
Sibelium does not provide the same role as an acute pain medicine. Taking a preventive tablet during an established migraine attack is unlikely to produce rapid relief.
| Clinical use | Main treatment role | Practical expectation |
|---|---|---|
| Migraine prevention | Reduces future attacks | Benefit develops gradually |
| Vestibular symptoms | May be selected for some vertigo patterns | Response depends on the underlying diagnosis |
| Circulation-related symptoms | Used only in selected clinical situations | Requires assessment of the cause |
The European Medicines Agency describes flunarizine as requiring careful assessment of neurological and psychiatric adverse effects, especially during prolonged treatment [1].
The active ingredient is flunarizine. It belongs to the calcium-channel blocker class and is used mainly for migraine prevention and selected vestibular or circulation-related indications.
The tablet should be swallowed as prescribed. Do not crush or chew it unless a prescriber has specifically given different instructions.
Calcium-channel blockers influence the movement of calcium across cell membranes. In migraine biology, excessive neuronal excitability and changes in cerebral blood-vessel tone can contribute to the development of an attack. Flunarizine is used between attacks to reduce this tendency rather than to stop established pain immediately.
Flunarizine can reduce neuronal excitability. Its central nervous system effects can cause drowsiness.
The amount of Sibelium used and how often it is taken depend on the purpose of treatment and are agreed with a doctor or pharmacist. The regimen may differ according to age, migraine pattern, treatment response, sedation, weight changes, and other medicines.
Typical prescribing practice may favour a regular schedule, often in the evening when drowsiness is a concern. The exact regimen belongs to the individual prescription.
Key administration points include:
Sibelium is intended as preventive therapy. It may need several weeks of regular use before the effect can be judged properly, and headache frequency should be recorded during treatment.
Preventive treatment is selected according to the patient’s diagnosis, blood pressure, sleep pattern, mood, weight, pregnancy status, and other medicines. Flunarizine has a different profile from beta-blockers and anticonvulsant medicines.
| Preventive approach | Main pharmacological feature | Common limitation |
|---|---|---|
| Flunarizine | Calcium-channel modulation with central nervous system effects | Sleepiness, increased appetite, weight gain, and movement-related reactions |
| Beta-blocker therapy | Reduces adrenergic cardiovascular activity | May worsen asthma, slow the pulse, or reduce exercise tolerance |
| Anticonvulsant therapy | Reduces neuronal hyperexcitability through different pathways | Cognitive, mood, metabolic, or reproductive safety concerns may limit use |
A clinician may prefer flunarizine when a calcium-channel approach fits the patient’s history and when its sedating effect is manageable. Another preventive class may be more suitable when the patient has depression, Parkinsonian symptoms, asthma, low blood pressure, marked obesity, or a complex interaction profile.
The choice is not based on headache pain alone. The pattern of attacks and the patient’s wider health profile influence the decision.
Several practical errors can make the treatment appear ineffective or increase avoidable side effects:
One common mistake is blaming every episode of dizziness on migraine. Dizziness may also reflect low blood pressure, another medicine, dehydration, an inner-ear disorder, or a neurological problem.
Flunarizine is also unsuitable for patients with a previous serious reaction to the ingredient.
The World Health Organization emphasises medication review when neurological symptoms, sedation, and multiple medicines occur together [2].
This medication is not for you if you have a current depressive illness that could worsen with treatment, a history of Parkinson’s disease, or another established movement disorder unless a specialist has specifically approved its use. Flunarizine is also unsuitable for patients with a previous serious reaction to the ingredient.
A new tremor, shuffling gait, unusual facial movements, persistent low mood, or loss of interest in usual activities requires medical review. These symptoms should not be managed by simply reducing the tablet without advice.
Flunarizine can cause drowsiness, fatigue, dizziness, increased appetite, and weight gain. These effects may appear early in treatment and can affect concentration or driving. Some patients experience dry mouth, nausea, or gastrointestinal discomfort.
Possible adverse effects include:
Movement-related symptoms need prompt medical attention. Tardive dyskinesia refers to repetitive involuntary movements that may involve the mouth, tongue, face, or limbs. Parkinsonism-like symptoms can include stiffness, tremor, reduced facial expression, and slowed movement.
Weight should be monitored when treatment continues for several months. A patient who notices steadily increasing appetite or clothes becoming tighter should report the change early rather than waiting for the next routine review.
Alcohol can intensify sedation and dizziness. Combining the two may impair coordination more than either exposure alone.
In clinical practice, doctors usually assess Sibelium by counting headache days over time rather than judging the result after one or two tablets. A preventive medicine can be useful even when attacks do not disappear completely, provided the frequency, severity, or rescue-medicine use falls.
A neurologist will usually consider the patient’s mood, movement symptoms, body weight, sleep quality, blood pressure, and current medicines before continuing treatment. Flunarizine may be a poor fit for a patient who already has depression, tremor, rigidity, or troublesome daytime sedation.
Doctors also distinguish prevention from acute treatment. Sibelium is not designed to replace an individual emergency plan for an attack that has already started. The preventive regimen and acute treatment plan should be assessed separately.
Pregnancy and breastfeeding require a specific risk assessment before flunarizine is used. The EMA's 2019 guidance advises that medicine exposure during pregnancy and lactation should be considered against the expected benefit, with special attention to medicines affecting the central nervous system [3]. Do not start, stop, or continue Sibelium for these situations without a documented plan from the prescriber.
The American Headache Society's 2021 consensus guidance supports regular sleep, consistent meals, adequate hydration, moderate exercise, and identification of personal triggers. Skipping meals, dehydration, sudden sleep changes, and excessive caffeine may increase migraine susceptibility in some people. A diary is more useful than removing many foods at once because it can reveal a repeatable personal pattern.
Alcohol can increase flunarizine-related drowsiness, dizziness, and impaired coordination. The WHO’s 2024 medication-safety principles support avoiding combinations that produce additive central nervous system depression [4]. Alcohol is best avoided while the individual response is being assessed, especially during the first days or after a dose change.
The FDA's 2023 medicine-storage guidance advises keeping medicines in a dry place away from excessive heat, moisture, and direct sunlight, while keeping tablets inaccessible to children [5]. During travel, keep the tablets in their original dispensing container and avoid leaving them in a parked vehicle, bathroom, or checked luggage. Carry the prescribed supply in hand luggage when travelling by air.
Stopping can allow the underlying migraine pattern to return because the preventive effect does not permanently remove the tendency to migraine. Whether tapering is needed depends on treatment duration, the prescribed regimen, side effects, and the reason for stopping. The EMA's 2023 flunarizine safety information supports reviewing treatment continuation when depressive or movement-related symptoms appear.
Some patients notice fewer or less severe attacks after several weeks, while others need a longer observation period before the result is clear. NICE's 2025 migraine guidance recommends judging preventive treatment through attack frequency, disability, and treatment use rather than one isolated episode. A headache diary gives the prescriber a practical basis for deciding whether the regimen is helping.
Use in children and adolescents requires a clinician’s assessment because migraine diagnosis, dosing, sedation, weight effects, and movement-related risks differ from adults. The American Academy of Neurology’s paediatric migraine guidance published in 2019 supports diagnosis-specific preventive planning rather than automatic use of adult regimens. A child or teenager should receive Sibelium only when a qualified prescriber has selected it for that individual.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
